The Carlyle Group shells out $435M for controlling stake in vaccine, gene therapy services company

Josh Sullivan

The Carlyle Group has put a target on life sciences in recent years, looking for opportunities to take controlling stakes in promising firms. After shelling …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

The Carlyle Group shells out $435M for controlling stake in vaccine, gene therapy services company

Josh Sullivan

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA says Ozempic, Wegovy shortage is over

Will CRISPR matter?

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

The Car­lyle Group shells out $435M for con­trol­ling stake in vac­cine, gene ther­a­py ser­vices com­pa­ny

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

The Carlyle Group shells out $435M for controlling stake in vaccine, gene therapy services company